Core Insights - The company Shiyao Group (01093) has received FDA approval for its GLP-1/GIP receptor dual agonist peptide injection (SYH2069), allowing clinical trials to commence in the United States [1] - This product is expected to be the first GLP-1/GIP dual agonist to enter clinical stages in China, with a mechanism that selectively activates the cAMP pathway while significantly reducing β-arrestin recruitment, leading to improved efficacy and sustained effects [1] - The product demonstrates superior weight loss and metabolic improvement in studies involving diet-induced obesity (DIO) mice and non-human primates compared to existing products [1] - Toxicology studies in non-human primates indicate good tolerability with no observed vomiting or gastrointestinal adverse reactions, suggesting excellent efficacy and safety [1] - The approved clinical indication focuses on weight management for obese or overweight individuals with at least one weight-related comorbidity, and it also shows potential for improving blood glucose control in adults with type 2 diabetes mellitus (T2DM), indicating high clinical development value [1]
石药集团：GLP-1/GIP受体双偏向性激动多肽注射液在美国获临床试验批准